JAK2基因突变在急性髓细胞白血病中的研究进展

doi:10.16150/j.1671-2870.2020.02.019

摘要/Abstract

中图分类号:

R551.3

徐娜娜, 吴涛, 寇明坤, 白海. JAK2基因突变在急性髓细胞白血病中的研究进展[J]. 诊断学理论与实践, 2020, 19(02): 195-198.

参考文献 25

[1]	Abdel-Wahab O, Manshouri T, Patel J, et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias[J]. Cancer Res, 2010, 70(2):447-452. doi: 10.1158/0008-5472.CAN-09-3783 pmid: 20068184
[2]	Wang S, Yan J, Zhou G, et al. Myeloproliferative neoplasm or reactive process? A rare case of acute myeloid leukemia and transient posttreatment megakaryocytic hyperplasia with JAK-2 mutation[J]. Case Rep Hematol, 2016, 2016:6054017.
[3]	Seavey MM, Dobrzanski P. The many faces of Janus kinase[J]. Biochem Pharmacol, 2012, 83(9):1136-1145. doi: 10.1016/j.bcp.2011.12.024 URL
[4]	Saharinen P, Vihinen M, Silvennoinen O. Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain[J]. Mol Biol Cell, 2003, 14(4):1448-1459. pmid: 12686600
[5]	Lee HJ, Daver N, Kantarjian HM, et al. The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia[J]. Clin Cancer Res, 2013, 19(2):327-335. doi: 10.1158/1078-0432.CCR-12-2087 URL
[6]	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders[J]. N Engl J Med, 2005, 352(17):1779-1790. doi: 10.1056/NEJMoa051113 URL
[7]	成志勇, 黄月华, 梁文同, 等. 骨髓增殖性肿瘤中JAK2 V617F突变与Ⅰ型细胞因子受体相关性研究[J]. 中国全科杂志, 2012, 15(9):1019-1022.
[8]	陈秀花, 王宏伟, 覃艳红, 等. JAK2 V617F阴性真性红细胞增多症患者JAK2 exon 12的突变研究[J]. 中华内科杂志, 2010, 49(9):797-798.
[9]	Lundberg P, Takizawa H, Kubovcakova L, et al. Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F[J]. J Exp Med, 2014, 211(11):2213-2230. doi: 10.1084/jem.20131371 URL
[10]	Medinger M, Skoda R, Gratwohl A, et al. Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status[J]. Br J Haematol, 2009, 146(2):150-157. doi: 10.1111/j.1365-2141.2009.07726.x URL
[11]	Nunes DP, Lima LT, Chauffaille Mde L, et al. CALR mutations screening in wild type JAK2(V617F) and MPL(W515K/L) Brazilian myeloproliferative neoplasm patients[J]. Blood Cells Mol Dis, 2015, 55(3):236-240. doi: 10.1016/j.bcmd.2015.07.005 URL
[12]	Theocharides A, Boissinot M, Girodon F, et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproli-ferative disorders are frequently negative for the JAK2-V617F mutation[J]. Blood, 2007, 110(1):375-379. doi: 10.1182/blood-2006-12-062125 pmid: 17363731
[13]	Aynardi J, Manur R, Hess PR, et al. JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group[J]. Br J Haematol, 2018, 182(1):78-85. doi: 10.1111/bjh.15276 URL
[14]	Scott LM, Rebel VI. JAK2 and genomic instability in the myeloproliferative neoplasms: a case of the chicken or the egg?[J]. Am J Hematol, 2012, 87(11):1028-1036. doi: 10.1002/ajh.23243 URL
[15]	Benton CB, Boddu PC, DiNardo CD, et al. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia[J]. Cancer, 2019, 125(11):1855-1866. doi: 10.1002/cncr.31986 URL
[16]	Marty C, Saint-Martin C, Pecquet C, et al. Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors[J]. Blood, 2014, 123(9):1372-1383. doi: 10.1182/blood-2013-05-504555 URL
[17]	Plo I, Nakatake M, Malivert L, et al. JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative di-sorders[J]. Blood, 2008, 112(4):1402-1412.
[18]	宗香萍, 汤林, 岑建农, 等. 异基因造血干细胞移植治疗原发性血小板增多症转化的急性髓系白血病三例报告并文献复习[J]. 中华血液学杂志, 2017, 38(10):883-886.
[19]	Vicente C, Vázquez I, Marcotegui N, et al. JAK2-V617F activating mutation in acute myeloid leukemia: prognostic impact and association with other molecular markers[J]. Leukemia, 2007, 21(11):2386-2390. pmid: 17581610
[20]	沈益民, 晁红颖, 张日, 等. 80例急性髓性白血病M₂型患者JAK2 V617F基因突变的检测及临床意义[J]. 中华肿瘤杂志, 2009, 31(5):366-370.
[21]	禹文君, 陈丽娟, 李建勇, 等. JAK2 V617F突变阳性原发性血小板增多症转化为JAK2 V617F突变阴性急性髓系白血病一例报告并文献复习[J]. 中华血液学杂志, 2014, 35(12):1122-1123.
[22]	Celgene Corporation. INREBIC® (fedratinib) capsules, for oral use: US prescribing information[R/OL]. 2019-08-16[2020-01-13]. http://www.fda.gov/.
[23]	Celgene Corporation. U.S. FDA approves INREBIC® (fedratinib) as frst new treatment in nearly a decade for patients with myelofbrosis[R/OL]. 2019-08-16[2020-01-13]. http://ir.celgene.com.
[24]	Sun J, Du Y, Zhang X, et al. Discovery and evaluation of Atopaxar hydrobromide, a novel JAK1 and JAK2 inhibitor, selectively induces apoptosis of cancer cells with constitutively activated STAT3[J/OL]. Invest New Drugs, 2019-10-14[2020-01-13]https://www.ncbi.nlm.nih.gov/pubmed/31612426.
[25]	Takagi S, Masuoka K, Uchida N, et al. Allogeneic hematopoietic cell transplantation for leukemic transformation preceded by philadelphia chromosome-negative myeloproliferative neoplasms: A nationwide survey by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation[J]. Biol Blood Marrow Transplant, 2016, 22(12):2208-2213. doi: 10.1016/j.bbmt.2016.09.017 URL

JAK2基因突变在急性髓细胞白血病中的研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 25

相关文章 14

编辑推荐

Metrics

本文评价

[1]	卢兴国. 骨髓增殖性肿瘤骨髓组织病理学诊断的新认识[J]. 诊断学理论与实践, 2020, 19(04): 434-437.
[2]	肖志坚. 我国骨髓增殖性肿瘤的诊治现状及挑战[J]. 诊断学理论与实践, 2020, 19(02): 101-103.
[3]	钱军. 骨髓增殖性肿瘤的分子诊断进展[J]. 诊断学理论与实践, 2020, 19(02): 104-110.
[4]	王舒, 张赟翔, 眭竫旎, 鲁静, 范惠咏, 王超, 陈冰. 正常核型急性髓细胞白血病中CEBPA基因伴随突变模式分析[J]. 诊断学理论与实践, 2017, 16(05): 498-503.
[5]	常春康,. 骨髓增殖性肿瘤中的钙网蛋白基因突变[J]. 诊断学理论与实践, 2015, 14(02): 105-108.
[6]	肖超, 常春康,. 慢性骨髓增殖性肿瘤临床研究进展[J]. 诊断学理论与实践, 2014, 13(06): 628-631.
[7]	张燕香, 魏蓉,. BCR-ABL阴性的骨髓增殖性肿瘤JAK2基因V617F突变分析[J]. 诊断学理论与实践, 2013, 12(03): 299-303.
[8]	王莹, 诸江, 胡炯,. 丙戊酸钠诱导髓系白血病细胞分化相关的分子标志物研究[J]. 诊断学理论与实践, 2011, 10(05): 434-439.
[9]	. 更正信息[J]. 诊断学理论与实践, 2011, 10(03): 292-.
[10]	薛永权,. 急性髓细胞白血病的染色体改变及其意义[J]. 诊断学理论与实践, 2011, 10(02): 186-188.
[11]	鲁怀亚,卢兴国. 急性白血病和骨髓增生异常综合征分型的进展[J]. 诊断学理论与实践, 2003, 2(03): 78-80.
[12]	熊树民. 急性白血病MICM分型诊断[J]. 诊断学理论与实践, 2002, 1(02): 17-19.
[13]	时昊,张日,朱子玲,耿美菊. 干细胞因子受体在急性白血病病人中的表达及其临床意义[J]. 诊断学理论与实践, 2002, 1(02): 41-42+45.
[14]	顾敏晔,熊树民. 伴有t(8;21)的急性髓细胞白血病M_(2b)型病人的临床特征(附67例报告)[J]. 诊断学理论与实践, 2002, 1(02): 29-30.